Florida, USA-based biotech Hesperos has published early-stage research into a novel drug development technology that has caught the attention of French pharma major Sanofi (Euronext: SAN).
Hesperos is pioneering the use of an in vitro cell-based system, branded Human-on-a-Chip, to mimic the physiological characteristics of certain diseases.
The firm’s latest research paper, available in the journal Advanced Therapeutics, describes work on two rare autoimmune demyelinating neuropathies, demonstrating the potential of the system in evaluating novel therapeutics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze